Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azasetron

Drug Profile

Azasetron

Alternative Names: Nazasetron; Serotone; Y 25130

Latest Information Update: 20 Feb 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Tobacco; Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Torii Pharmaceutical; University of California at San Francisco
  • Class Antiemetics; Antineoplastics; Heterocyclic bicyclo compounds; Oxazines
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Nausea and vomiting
  • Discontinued Cocaine abuse; Gastrointestinal disorders

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 08 May 2007 Discontinued - Preclinical for Cocaine abuse in USA (unspecified route)
  • 16 May 2002 Discontinued - Phase-II for Gastrointestinal disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top